DK2818482T3 - Farmaceutisk sammensætning til behandling af cancer - Google Patents

Farmaceutisk sammensætning til behandling af cancer Download PDF

Info

Publication number
DK2818482T3
DK2818482T3 DK13751278.6T DK13751278T DK2818482T3 DK 2818482 T3 DK2818482 T3 DK 2818482T3 DK 13751278 T DK13751278 T DK 13751278T DK 2818482 T3 DK2818482 T3 DK 2818482T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
cancer treatment
cancer
treatment
pharmaceutical
Prior art date
Application number
DK13751278.6T
Other languages
Danish (da)
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK2818482T3 publication Critical patent/DK2818482T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK13751278.6T 2012-02-21 2013-02-21 Farmaceutisk sammensætning til behandling af cancer DK2818482T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (ja) 2012-02-21 2013-02-21 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
DK2818482T3 true DK2818482T3 (da) 2019-07-15

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13751278.6T DK2818482T3 (da) 2012-02-21 2013-02-21 Farmaceutisk sammensætning til behandling af cancer

Country Status (16)

Country Link
US (1) US9273130B2 (enExample)
EP (1) EP2818482B1 (enExample)
JP (1) JP6187255B2 (enExample)
KR (1) KR102009238B1 (enExample)
CN (1) CN104169303B (enExample)
AU (1) AU2013223143B2 (enExample)
CA (1) CA2864864C (enExample)
DK (1) DK2818482T3 (enExample)
ES (1) ES2739612T3 (enExample)
HU (1) HUE044611T2 (enExample)
IN (1) IN2014KN01713A (enExample)
MX (1) MX360208B (enExample)
PL (1) PL2818482T3 (enExample)
PT (1) PT2818482T (enExample)
RU (1) RU2632645C2 (enExample)
WO (1) WO2013125636A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
WO2011096534A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
AU2012290949B2 (en) * 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR101984554B1 (ko) * 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
PL2832365T3 (pl) * 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
PL2876446T3 (pl) 2012-07-19 2019-06-28 Toray Industries, Inc. Sposób wykrywania nowotworu
WO2014031174A1 (en) 2012-08-24 2014-02-27 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
AU2019242520A1 (en) 2018-03-30 2020-10-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220034784A (ko) 2019-06-13 2022-03-18 볼트 바이오테라퓨틱스 인코퍼레이티드 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
KR20220088901A (ko) 2019-10-25 2022-06-28 볼트 바이오테라퓨틱스 인코퍼레이티드 티에노아제핀 면역접합체, 및 이의 용도
JPWO2021182573A1 (enExample) 2020-03-12 2021-09-16
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
EP4119159A4 (en) 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CA3175277A1 (en) * 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182574A1 (enExample) 2020-03-12 2021-09-16
EP4146282A1 (en) 2020-05-08 2023-03-15 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4196168A1 (en) 2020-08-13 2023-06-21 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
CA3225420A1 (en) 2021-06-23 2022-12-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3225422A1 (en) 2021-06-23 2022-12-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022320304A1 (en) * 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023008459A1 (enExample) 2021-07-27 2023-02-02
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むtlrアゴニスト免疫複合体、及びその使用
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024043252A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
AU2023329563A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2024043258A1 (enExample) 2022-08-24 2024-02-29
KR20250053841A (ko) 2022-08-30 2025-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20250054778A (ko) 2022-08-30 2025-04-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
KR20250118852A (ko) 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
BR9909382A (pt) 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2388822A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CZ20023567A3 (cs) 2000-03-29 2003-11-12 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
KR100770065B1 (ko) 2001-05-11 2007-10-24 기린 파마 가부시끼가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는비인간 동물
AU2002311909A1 (en) 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
PL1735348T3 (pl) 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
ATE515515T1 (de) 2004-03-30 2011-07-15 Glaxo Group Ltd Immunglobuline gegen menschlisches osm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
KR101633351B1 (ko) 2007-10-25 2016-06-27 도레이 카부시키가이샤 암의 검출 방법
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
KR102449659B1 (ko) 2008-03-18 2022-09-29 제넨테크, 인크. 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
WO2010014813A2 (en) * 2008-07-31 2010-02-04 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
ES2619322T3 (es) 2008-08-05 2017-06-26 Toray Industries, Inc. Agente inductor de inmunidad
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
WO2011020529A2 (en) 2009-08-19 2011-02-24 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
AU2010297580B2 (en) 2009-09-22 2014-07-31 Probiogen Ag Process for producing molecules containing specialized glycan structures
RU2418587C1 (ru) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Способ лечения злокачественных опухолей головного мозга
CA2788547C (en) * 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
DK2532367T3 (en) * 2010-02-04 2018-11-19 Toray Industries PHARMACEUTICAL AGENT FOR TREATMENT AND / OR CANCER PREVENTION
WO2011096534A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532366T3 (pl) 2010-02-04 2017-02-28 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
NZ606195A (en) 2010-07-26 2015-02-27 Servier Lab Methods and compositions for liver cancer therapy
JP2012035484A (ja) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd 塗膜転写具
KR101984554B1 (ko) 2011-08-04 2019-05-31 도레이 카부시키가이샤 췌장암의 검출 방법
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
HUE033149T2 (en) 2011-08-04 2017-11-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby

Also Published As

Publication number Publication date
AU2013223143A1 (en) 2014-09-11
HUE044611T2 (hu) 2019-11-28
EP2818482A4 (en) 2015-10-07
CA2864864C (en) 2020-05-12
CN104169303A (zh) 2014-11-26
EP2818482B1 (en) 2019-05-22
US9273130B2 (en) 2016-03-01
EP2818482A1 (en) 2014-12-31
RU2014138040A (ru) 2016-04-10
JP6187255B2 (ja) 2017-08-30
JPWO2013125636A1 (ja) 2015-07-30
PL2818482T3 (pl) 2019-11-29
IN2014KN01713A (enExample) 2015-10-23
BR112014021101A2 (pt) 2022-03-22
WO2013125636A1 (ja) 2013-08-29
KR102009238B1 (ko) 2019-08-09
ES2739612T3 (es) 2020-02-03
US20150004171A1 (en) 2015-01-01
AU2013223143B2 (en) 2017-12-21
MX360208B (es) 2018-10-24
KR20140130668A (ko) 2014-11-11
RU2632645C2 (ru) 2017-10-06
CN104169303B (zh) 2018-05-29
PT2818482T (pt) 2019-08-06
MX2014009748A (es) 2014-11-14
CA2864864A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3470063T3 (da) Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK2694038T3 (da) Farmaceutisk sammensætning
FR2997014B1 (fr) Composition sterile dermo-injectable
BR112015002738A2 (pt) composto , e , composição farmacêutica
PT2854768T (pt) Composições farmacêuticas de pemetrexed
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
EP2934454C0 (en) ANTI-DANDRUFF COMPOSITION
DK2897594T3 (da) Farmaceutisk sammensætning
DK3511004T3 (da) Kombineret præparat til behandling af cancer
ES2721400T8 (es) Composición de Diclofenaco
DK3290035T3 (da) Procaspase-kombinationsterapi til behandling af cancer
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
EP2769718A4 (en) MEDICAL COMPOSITION
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK2812013T3 (da) Formulering til behandling af IBS
EP2883547A4 (en) MEDICINE
DK3524260T3 (da) Farmaceutiske sammensætninger til behandling af manglende appetit